Biotech Values

[pharmaclown35]

i wonder if all this talk and push for biomarkers is actually doing more harm in terms of drug development costs. it must be so much costlier to conduct biomarker trials. that will prob slow down R&D in the short term ??

also, tarceva phase III SATURN trial results testing as maintainence therapy in NSCLC is coming out soon in Q408. might run into some issues with pt selection, like EGFR mutations. that should be interesting. but it should only work in a small population regardless. i wonder if there is really much value in tarceva as maintenencen therapy in NSCLC.